Skip to main content
. 2022 Dec 8;9(2):215–224. doi: 10.1001/jamaoncol.2022.5816

Figure 2. Kaplan-Meier Plots for Overall Survival in Low Programmed Death Ligand 1 (PD-L1) Subgroups Derived With KMSubtraction (Studies With the Combined Positive Score [CPS] Available).

Figure 2.

A, In the global multinational studies on pembrolizumab, the first-line KEYNOTE-590 trial subgroup with a CPS lower than 10 demonstrated no significant difference in overall survival for immunochemotherapy compared with chemotherapy alone (hazard ratio [HR], 0.91; 95% CI, 0.69-1.20; P = .50). B, In the second-line KEYNOTE-181 trial, for the subgroup with a CPS lower than 10, there was no significant difference in overall survival for immunotherapy compared with chemotherapy alone (HR, 0.90; 95% CI, 0.68-1.18; P = .44). C, In the sintilimab-based ORIENT-15 trial, for the subgroup with a CPS lower than 10, there was a significant difference in overall survival for immunochemotherapy compared with chemotherapy (HR, 0.62; 95% CI, 0.45-0.85; P = .003).